Development and Efficacy Evaluation of Integrated Chronic Care and Health Promotion Model for Patients With Coronary Artery Disease in Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital400 enrolled

Overview

The hypothesis of this project is to examine whether the integrated health care program as the intervention group can reduce the recurrence and mortality of coronary artery-related diseases than the traditional one as the comparison group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

400

Conditions

Acute Myocardial Infarction Stable Angina

Interventions

Integrated health care teamBEHAVIORAL

CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring

Traditional groupOTHER

CAD education fryers

Eligibility

Sex: ALLMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients who suffered from acute myocardial infarction or stable angina with intervention (CABG or PTCA) Exclusion Criteria: 1. Age \> 85 yrs old. 2. Worse short-term prognosis (e.g.cancer, congestive heart failure NYHA IV) 3. Any systemic disease which will limit the exercise program (e.g. bed-ridden stroke) 4. Unable to participate in the trial due to any logic reasons

Locations (1)

Kaohsiung Medical University Hospital

Kaohsiung, Taiwan, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Death, non-fatal MI, non-fatal stroke, recurrent angina, emergency room (ER) visit due to any CV-related diseases or readmission due to any CV-related diseases confirmed by the physicians.

Time frame: one year

Secondary Outcomes

BP, lipid, glucose, EBM drugs and self-care efficacy

1. Blood pressure \< 140/90 mmHg (\< 130/80 mmHg in the diabetics and patients with chronic kidney disease) 2. Hypercholesterolemia：LDL \< 100 mg/dl 3. Diabetic：HbA1c \< 7% 4. Smoking cessation rate 5. Adherence rate of EBM medication including anti-platelet agent, beta-blocker, RAS blocker and lipid-lowering agent. 6. Efficacy of self care

Time frame: one year

Central Contacts

Sheng-Hsiung Sheu, MD

CONTACT

88673121101 Sheush@kmu.edu.tw

Tsung-Hsien Lin, MD. PHD

CONTACT

88673121101 lth@kmu.edu.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.